What is the average weight gain associated with Nexplanon (etonogestrel implant)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Average Weight Gain with Nexplanon

Based on FDA labeling data, users of Nexplanon (etonogestrel implant) experience an average weight gain of 2.8 pounds (1.3 kg) after one year and 3.7 pounds (1.7 kg) after two years of use 1.

Clinical Context and Variability

The FDA label explicitly states that the extent to which this weight gain is directly attributable to the implant versus natural weight changes remains unknown 1. This is a critical counseling point, as weight gain patterns show substantial individual variation.

Weight Gain Patterns Over Time

Research data corroborates and extends the FDA findings:

  • Year 1: Approximately 2.1 kg mean gain 2
  • Year 2: Approximately 3.0 kg cumulative gain 3
  • Year 3: Approximately 3.0-3.3 kg cumulative gain 3, 4

The most recent large-scale study from 2024 found a mean BMI increase of +1.0 at 36 months compared to controls 5, which translates to roughly 2-3 kg for most women.

Important Clinical Nuances

Individual Variation is Substantial

Approximately 38-40% of Nexplanon users either lose weight or experience no net weight change 4, 6. Among those who do gain weight:

  • 36% gain 1-5 kg
  • 19% gain 6-10 kg
  • 4% gain 11-15 kg
  • 2% gain >16 kg 4

Weight Category Considerations

Baseline weight is the strongest predictor of final body weight (predicts 83.5% of variance) 4. However, overweight and obese adolescents do not experience accelerated weight gain after implant insertion compared to their pre-insertion trajectory 7. The implant does not appear to worsen existing weight gain trends in higher-weight individuals.

Race as a Risk Factor

Black race is independently associated with greater weight gain (additional 1.3 kg) when using progestin-only contraceptives 2. This is an important consideration for individualized counseling.

Discontinuation Due to Weight Concerns

Only 2.3-3.8% of users request early removal specifically due to weight gain 1, 4. However, those who do remove the implant for weight concerns demonstrate significantly more weight gain (65.5% gained ≥5% body weight) compared to those who continue use 7.

Comparison to Other Methods

When compared head-to-head:

  • Nexplanon vs copper IUD: Nexplanon users gained approximately 0.76-0.79 kg more per year in women >50 kg 3
  • Nexplanon vs DMPA: Similar weight gain patterns (2.1 kg vs 2.2 kg at 12 months) 2
  • Nexplanon vs levonorgestrel implant: Virtually identical (3.0 kg vs 2.9 kg at 36 months) 3

Counseling Recommendations

When discussing weight with patients considering Nexplanon:

  1. Set realistic expectations: Average gain is modest (2-4 pounds over 1-2 years)
  2. Emphasize variability: Nearly 40% of users don't gain weight
  3. Address baseline weight: Initial body weight is the strongest predictor of final weight
  4. Acknowledge uncertainty: The causal relationship between the implant and weight gain is not definitively established
  5. Consider race: Black patients may experience slightly more weight gain
  6. Monitor but don't overreact: Weight changes comparable to natural fluctuations and other contraceptive methods

The 2024 study conclusion is particularly relevant: these BMI changes "may not be clinically concerning" despite being statistically significant 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.